Moonlake Immunotherapeutics (MLTX)

Sep 25, 2026

MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits

Sep 25, 2026

Sep 24, 2026

MoonLake Immunotherapeutics (MLTX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat

Sep 24, 2026

Sep 22, 2026

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High? - Eastern Progress

Sep 22, 2026

Sep 22, 2026

Technical Reactions to MLTX Trends in Macro Strategies - Stock Traders Daily

Sep 22, 2026

Sep 21, 2026

Did Positive Phase III Results Just Shift MoonLake Immunotherapeutics Stock Investment Narrative? - simplywall.st

Sep 21, 2026

Sep 21, 2026

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight - GlobeNewswire Inc.

Sep 21, 2026

Sep 18, 2026

Moonlake Immunotherapeutics Stock Price Forecast. Should You Buy MLTX? - StockInvest.us

Sep 18, 2026

Sep 16, 2026

Cantor Fitzgerald reiterates Moonlake stock rating at Overweight By Investing.com - Investing.com South Africa

Sep 16, 2026

Sep 16, 2026

Cantor Fitzgerald reiterates Moonlake stock rating at Overweight - Investing.com

Sep 16, 2026

Sep 13, 2026

TSLA: Tesla Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 13, 2026

Sep 12, 2026

MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits

Sep 12, 2026

Sep 12, 2026

MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits

Sep 12, 2026

Sep 12, 2026

(MLTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Sep 12, 2026

Sep 11, 2026

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits

Sep 11, 2026

Sep 11, 2026

MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near - Stocktwits

Sep 11, 2026

Sep 08, 2026

MoonLake Immunotherapeutics advances sonelokima... - Pluang

Sep 08, 2026

Sep 08, 2026

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy - Seeking Alpha

Sep 08, 2026

Sep 07, 2026

GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 07, 2026

Aug 26, 2026

3 takeover targets in immunology - Pharma Voice

Aug 26, 2026

Aug 21, 2026

MoonLake reports positive phase 3 psoriatic arthritis trial results By Investing.com - Investing.com Nigeria

Aug 21, 2026

Aug 20, 2026

Deep Track Capital, LP Expands MoonLake Immunotherapeutics (MLTX) Stake With 1.59 Million Share Purchase - GuruFocus

Aug 20, 2026

Aug 20, 2026

MoonLake (MLTX) Quarterly Figures: Profit Per Share Falls Below Its Benchmark in the Available Record; Closing Move - Vinanet

Aug 20, 2026

Aug 20, 2026

Lost Money on MoonLake Immunotherapeutics (MLTX)? Urged to Join C - The National Law Review

Aug 20, 2026

Aug 20, 2026

MoonLake (MLTX) Financial Results: EPS Does Not Reach the Reported Estimate; After Results: Shares Finish 5.97% Lower on the DayEarnings Recovery Stocks - vinanet.vn

Aug 20, 2026

Aug 19, 2026

Class Action Alert: Levi & Korsinsky Reminds MoonLake (MLTX) Investors of December 15, 2025 Deadline - The National Law Review

Aug 19, 2026

Aug 19, 2026

Why is MoonLake Immunotherapeutics stock plunging today? By Investing.com - Investing.com Nigeria

Aug 19, 2026

Aug 18, 2026

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - Stocktwits

Aug 18, 2026

Aug 18, 2026

MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week - Stocktwits

Aug 18, 2026

Aug 18, 2026

Why Did MLTX Stock Rise After-Hours Today? - Stocktwits

Aug 18, 2026

Aug 16, 2026

Dimensional Fund Advisors LP Has $490,000 Position in MoonLake Immunotherapeutics $MLTX - marketbeat.com

Aug 16, 2026

Aug 14, 2026

Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake - Stock Titan

Aug 14, 2026

Aug 14, 2026

T. Rowe Price (MLTX holder) discloses 5.3% MoonLake Immunotherapeutics position - Stock Titan

Aug 14, 2026

Aug 14, 2026

Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A - Stock Titan

Aug 14, 2026

Aug 13, 2026

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Aug 13, 2026

Aug 13, 2026

H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $50 - Moomoo

Aug 13, 2026

Aug 12, 2026

MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital - The Globe and Mail

Aug 12, 2026

Aug 12, 2026

MoonLake Immunotherapeutics (MLTX) Gets a Buy from BTIG - The Globe and Mail

Aug 12, 2026

Aug 12, 2026

MLTX LAWSUIT ALERT: Levi & Korsinsky Notifies MoonLake Immunother - The National Law Review

Aug 12, 2026

Aug 11, 2026

MoonLake's sonelokimab meets all endpoints in Phase 3 IZAR-1 psoriatic arthritis trial - Dealroom

Aug 11, 2026

Aug 11, 2026

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study - Sahm

Aug 11, 2026

Aug 11, 2026

Avoiding Lag: Real-Time Signals in (MLTX) Movement - Stock Traders Daily

Aug 11, 2026